Synthetic PAR1-mimetic peptide induces autophagy, regressing low-grade malignant breast tumors in mice by downregulating mTOR.
Background
Current breast cancer therapies often lack specificity and can have significant side effects. Autophagy, a cellular recycling process, is a promising therapeutic target, but few synthetic peptides exist that can specifically induce autophagy in cancer cells. The protease-activated receptor 1 (PAR1) pathway is implicated in cell proliferation via mTOR signaling when canonically activated by thrombin. This study explores a novel, noncanonical PAR1 activation mechanism that could offer a more targeted approach to inducing autophagy and combating breast cancer.
Study Design
Researchers investigated a synthetic peptide that mimics an N-terminal sequence generated by noncanonical activation of PAR1 by hemagglutinin protease (HAP). In vitro, they tested the synthetic peptide's ability to induce autophagy in both ER+/PR+/HER2- and triple-negative (ER-/PR-/HER2-) breast cancer cell lines. For in vivo studies, a BALB/c mouse model of low-grade malignant breast tumor was used. The synthetic peptide was administered to these mice, and its effects on tumor growth and progression were monitored. The study also assessed PAR1 expression in normal vs. cancerous breast cells.
Results
Noncanonical activation of PAR1 by HAP was found to downregulate mTOR activation and trigger autophagy in both ER+/PR+/HER2- and triple-negative breast cancer cells. The synthetic peptide, mimicking the N-terminal PAR1 sequence, independently induced autophagy in these breast cancer cells in vitro. Importantly, in the BALB/c mouse model of low-grade malignant breast tumor, the peptide-induced autophagy significantly inhibited tumor growth and delayed tumor progression. This effect was attributed to the peptide's selective targeting: normal, healthy breast epithelial cells lacked PAR1 expression, while breast cancer cells exhibited relatively high PAR1 expression. This differential expression facilitated the peptide's specific action.
The synthetic PAR1-mimetic peptide significantly inhibited tumor growth and delayed tumor progression in a mouse model of low-grade malignant breast tumor.
Key Findings
- Noncanonical
PAR1activation by HAP downregulatesmTORand triggers autophagy in breast cancer cells. - A synthetic peptide mimicking the
PAR1N-terminal sequence induces autophagy in breast cancer cells in vitro. - The synthetic peptide significantly inhibits tumor growth and delays progression in a mouse model of low-grade malignant breast tumor.
- Normal breast epithelial cells lack
PAR1expression, allowing the peptide to selectively targetPAR1-high breast cancer cells.
Why It Matters
This research introduces a novel, highly specific mechanism for targeting breast cancer cells through autophagy induction, potentially offering a new therapeutic avenue. The synthetic PAR1-mimetic peptide's ability to selectively target cancer cells while sparing healthy tissue is a critical advantage, addressing a major limitation of current chemotherapies. While preclinical, these findings suggest a future where peptide-based therapies could offer more precise and less toxic treatments for low-grade malignant breast tumors. Further research is needed to develop a usable clinical protocol, including optimal dosing, administration routes, and long-term safety profiles in humans, but the specificity shown here is a strong foundation.
breast-cancer
autophagy
par1
mTOR
peptide-therapy
preclinical-animal